journal
MENU ▼
Read by QxMD icon Read
search

JAMA Oncology

journal
https://www.readbyqxmd.com/read/30193367/information-transparency-in-the-drug-approval-process
#1
Brian I Rini, Harold J Burstein, Daniel J George
No abstract text is available yet for this article.
September 6, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30193359/information-transparency-in-the-drug-approval-process-reply
#2
Bishal Gyawali, Daniel A Goldstein
No abstract text is available yet for this article.
September 6, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30193328/terminal-cancer-and-death-on-grief
#3
Scott Bowman
No abstract text is available yet for this article.
September 6, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30193295/disease-free-and-overall-survival-among-patients-with-operable-her2-positive-breast-cancer-treated-with-sequential-vs-concurrent-chemotherapy-the-acosog-z1041-alliance-randomized-clinical-trial
#4
Aman U Buzdar, Vera J Suman, Funda Meric-Bernstam, Ann Marilyn Leitch, Matthew J Ellis, Judy C Boughey, Gary W Unzeitig, Melanie E Royce, Kelly K Hunt
Importance: Pathologic complete response rate (pCR), the primary end point of the ACOSOG (American College of Surgeons Oncology Group) Z1041 (Alliance) trial, and disease-free survival (DFS) and overall survival (OS) in women with operable HER2-positive breast cancer are similar between treatment regimens. Objective: To assess DFS and OS for patients treated with sequential vs concurrent anthracycline plus trastuzumab. Design, Setting, and Participants: Phase 3 randomized clinical trial conducted at 36 centers in the continental United States and Puerto Rico...
September 6, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30193254/clinical-trials-end-points-and-statistics-measuring-and-comparing-cancer-treatments-in-practice
#5
Howard West, Suzanne Dahlberg
No abstract text is available yet for this article.
September 6, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30193240/hyperprogressive-disease-in-patients-with-advanced-non-small-cell-lung-cancer-treated-with-pd-1-pd-l1-inhibitors-or-with-single-agent-chemotherapy
#6
Roberto Ferrara, Laura Mezquita, Matthieu Texier, Jihene Lahmar, Clarisse Audigier-Valette, Laurent Tessonnier, Julien Mazieres, Gerard Zalcman, Solenn Brosseau, Sylvestre Le Moulec, Laura Leroy, Boris Duchemann, Corentin Lefebvre, Remi Veillon, Virginie Westeel, Serge Koscielny, Stephane Champiat, Charles Ferté, David Planchard, Jordi Remon, Marie-Eve Boucher, Anas Gazzah, Julien Adam, Emilio Bria, Giampaolo Tortora, Jean-Charles Soria, Benjamin Besse, Caroline Caramella
Importance: Hyperprogressive disease (HPD) is a new pattern of progression recently described in patients with cancer treated with programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors. The rate and outcome of HPD in advanced non-small cell lung cancer (NSCLC) are unknown. Objectives: To investigate whether HPD is observed in patients with advanced NSCLC treated with PD-1/PD-L1 inhibitors compared with single-agent chemotherapy and whether there is an association between treatment and HPD...
September 6, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30178038/downstaging-and-survival-outcomes-associated-with-neoadjuvant-chemotherapy-regimens-among-patients-treated-with-cystectomy-for-muscle-invasive-bladder-cancer
#7
Charles C Peyton, Dominic Tang, Richard R Reich, Mounsif Azizi, Juan Chipollini, Julio M Pow-Sang, Brandon Manley, Philippe E Spiess, Michael A Poch, Wade J Sexton, Mayer Fishman, Jingsong Zhang, Scott M Gilbert
Importance: Neoadjuvant chemotherapy (NAC) followed by radical cystectomy improves survival compared with cystectomy alone for patients with bladder cancer. Although gemcitabine with cisplatin has become a standard NAC regimen, a dose-dense combination of methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) is being adopted at some institutions. Objective: To assess the association of neoadjuvant ddMVAC vs standard regimens with downstaging and overall survival among patients treated with radical cystectomy for bladder cancer...
August 30, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30178032/nab-paclitaxel-and-gemcitabine-as-first-line-treatment-of-advanced-or-metastatic-cholangiocarcinoma-a-phase-2-clinical-trial
#8
Vaibhav Sahai, Paul J Catalano, Mark M Zalupski, Sam Joseph Lubner, Mark R Menge, Halla Sayed Nimeiri, Hidayatullah G Munshi, Al Bowen Benson, Peter J O'Dwyer
Importance: Gemcitabine with platinum has limited efficacy for treatment of advanced cholangiocarcinoma, necessitating an evaluation of alternative drug combinations. Recent evidence suggests that paclitaxel may potentiate gemcitabine activity. Objective: To evaluate whether gemcitabine plus nanoparticle albumin-bound (nab)-paclitaxel is safe and effective for treatment of advanced cholangiocarcinoma. Design, Setting, and Participants: This single-arm, 2-stage, phase 2 clinical trial was conducted at 23 community and academic centers across the United States and Europe...
August 30, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30178024/financial-conflicts-of-interest-among-oncologist-authors-of-reports-of-clinical-drug-trials
#9
Cole Wayant, Erick Turner, Chase Meyer, Philip Sinnett, Matt Vassar
No abstract text is available yet for this article.
August 30, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30178021/management-of-liver-neuroendocrine-tumors-in-2018
#10
Deshka S Foster, Robert Jensen, Jeffrey A Norton
No abstract text is available yet for this article.
August 30, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30177994/safety-and-efficacy-of-bevacizumab-plus-standard-of-care-treatment-beyond-disease-progression-in-patients-with-advanced-non-small-cell-lung-cancer-the-avaall-randomized-clinical-trial
#11
Cesare Gridelli, Javier de Castro Carpeno, Anne-Marie C Dingemans, Frank Griesinger, Francesco Grossi, Corey Langer, Yuichiro Ohe, Konstantinos Syrigos, Nick Thatcher, Ashis Das-Gupta, Matt Truman, Margarita Donica, Vlatka Smoljanovic, Jaafar Bennouna
Importance: Bevacizumab treatment beyond progression has been investigated in breast and metastatic colorectal cancers. Avastin in All Lines Lung (AvaALL) is the first randomized phase 3 study of bevacizumab across multiple lines of treatment beyond progression in non-small cell lung cancer (NSCLC). Objective: To assess the efficacy and safety of continuous bevacizumab treatment beyond first progression in NSCLC. Design, Setting, and Participants: AvaALL was a randomized, open-label, phase 3b trial, conducted from 2011 to 2015 in 123 centers worldwide...
August 30, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30128567/improving-on-tail-of-the-curve-evaluation-with-the-american-society-of-clinical-oncology-value-framework
#12
Nathan I Cherny, Elisabeth G E de Vries
No abstract text is available yet for this article.
August 16, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30128551/redefining-the-value-proposition-of-precision-oncology-can-we-integrate-genomic-testing-without-overselling-it
#13
Howard Jack West
No abstract text is available yet for this article.
August 16, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30128536/association-of-breast-and-ovarian-cancers-with-predisposition-genes-identified-by-large-scale-sequencing
#14
Hsiao-Mei Lu, Shuwei Li, Mary Helen Black, Shela Lee, Robert Hoiness, Sitao Wu, Wenbo Mu, Robert Huether, Jefferey Chen, Srijani Sridhar, Yuan Tian, Rachel McFarland, Jill Dolinsky, Brigette Tippin Davis, Sharon Mexal, Charles Dunlop, Aaron Elliott
Importance: Since the discovery of BRCA1 and BRCA2, multiple high- and moderate-penetrance genes have been reported as risk factors for hereditary breast cancer, ovarian cancer, or both; however, it is unclear whether these findings represent the complete genetic landscape of these cancers. Systematic investigation of the genetic contributions to breast and ovarian cancers is needed to confirm these findings and explore potentially new associations. Objective: To confirm reported and identify additional predisposition genes for breast or ovarian cancer...
August 16, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30128502/assessment-of-safety-and-immunogenicity-of-pvx-410-vaccine-with-or-without-lenalidomide-in-patients-with-smoldering-multiple-myeloma-a-nonrandomized-clinical-trial
#15
Ajay K Nooka, Michael Luhua Wang, Andrew J Yee, Jonathan L Kaufman, Jooeun Bae, Doris Peterkin, Paul G Richardson, Noopur S Raje
Importance: Increasing evidence suggests the significance of the role of the immune system in the progression of smoldering multiple myeloma (SMM) to symptomatic multiple myeloma (MM). Boosting the immune system via vaccination in the earlier, asymptomatic SMM stage may provide a novel strategy to prevent or slow progression to active MM. Objective: To determine the safety, tolerability, immunogenicity, and anti-MM activity of the PVX-410 multipeptide vaccine with or without lenalidomide...
August 16, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30128501/hereditary-breast-and-ovarian-cancer-testing-in-the-genomic-era
#16
Stephanie L Greville-Heygate, Diana M Eccles, Lucy E Side
No abstract text is available yet for this article.
August 16, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30128500/improving-on-tail-of-the-curve-evaluation-with-the-american-society-of-clinical-oncology-value-framework-reply
#17
Omer Ben-Aharon, Daniel A Goldstein
No abstract text is available yet for this article.
August 16, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30128488/inconsistent-reporting-of-potential-conflicts-of-interest
#18
Vinay Prasad
No abstract text is available yet for this article.
August 16, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30128487/accuracy-and-methodologic-challenges-of-volatile-organic-compound-based-exhaled-breath-tests-for-cancer-diagnosis-a-systematic-review-and-meta-analysis
#19
George B Hanna, Piers R Boshier, Sheraz R Markar, Andrea Romano
Importance: The detection and quantification of volatile organic compounds (VOCs) within exhaled breath have evolved gradually for the diagnosis of cancer. The overall diagnostic accuracy of proposed tests remains unknown. Objectives: To determine the diagnostic accuracy of VOC breath tests for the detection of cancer and to review sources of methodologic variability. Data Sources: An electronic search (title and abstract) was performed using the Embase and MEDLINE databases (January 1, 2000, to May 28, 2017) through the OVID platform...
August 16, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30128482/missing-conflict-of-interest-disclosure
#20
(no author information available yet)
No abstract text is available yet for this article.
August 16, 2018: JAMA Oncology
journal
journal
50067
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"